FORTE BIOSCIENCES INC
FBRXNASDAQ🏆 #2144 by market capEarnings Nov 12US Equity
$654.00▼ $50.16 (−7.67%)
Simulated priceTrack FBRX
Get earnings, price moves & breaking news on Telegram
24h▼ 7.7%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$1.63B
Small Cap
📈Revenue Growth (YoY)
-99.8%
Declining
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
40860.7x
Expensive
Otter Score
56
Weak
No chart data available for FBRX.
Trading Snapshot
- Day Range
- $650.37 – $665.51
- 52-Week Range
- $10.30 – $77.20
- Volume
- $3.06B
- Avg Volume
- $3.97B
- Shares Outstanding
- 20.5M
- Next Earnings
- Nov 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $40,000
- Last Q Revenue
- $9,597
- P/E Ratio
- —
- P/S Ratio
- 40860.7x
- EPS (TTM)
- $-4.60
- Dividend Yield
- —
- Dilution (1yr)
- +179.4%
Why Investors Own FBRX
- ✓High-growth profile — revenue up +3.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 45% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
FORTE BIOSCIENCES INC
FBRXFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$71M▲ +93.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$51M▲ +65.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
17.9M▲ +179.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$77M▲ +$55M YoY
StockOtter · stockotter.spaceAbout FORTE BIOSCIENCES INC
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100
Analyst Ratings
ⓘConsensus
Buy
11 analysts
Strong Buy2
Buy4
Hold5
Sell0
Strong Sell0
Ratings as of Sep 2026
Latest News & Updates
🚀
Bloomberg·2h ago
FORTE BIOSCIENCES INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift FBRX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
FORTE BIOSCIENCES INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.